Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Mitral Regurgitation I: Introduction

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cellular Adaptation II: Hypertrophy

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Defining a High-Quality Living Kidney Donor Evaluation: A Delphi Survey and Consensus Conference Summary Report.

Canadian journal of kidney health and disease·2026

Same author

Canadian Society of Nephrology Commentary on the 2025 Kidney Disease Improving Global Outcomes Clinical Practice Guidelines for Autosomal Dominant Polycystic Kidney Disease.

Canadian journal of kidney health and disease·2026

Same author

Serum and urine prognostic biomarkers for autosomal dominant polycystic kidney disease: a systematic review and meta-analysis.

BMC nephrology·2026

Same author

Improving Risk Prediction in ADPKD.

Kidney international reports·2026

Same author

Pregnancy and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026

Same author

Eight Years of Canadian Real-World Assessment of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease: The C-MAJOR Registry.

Canadian journal of kidney health and disease·2026

Search research articles

Related Experiment Video

Updated: May 8, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Left ventricular hypertrophy in ADPKD: changing demographics.

Ahsan Alam¹, Ronald D Perrone

¹McGill University, Royal Victoria Hospital - McGill University Health Centre, 687Pine Avenue West, Montreal, Canada. H3A 1A1.

Current Hypertension Reviews

|August 27, 2013

Summary

Left ventricular hypertrophy (LVH) prevalence in autosomal dominant polycystic kidney disease (ADPKD) patients has decreased due to better hypertension management and RAAS antagonist use. This shift impacts cardiovascular risk management in ADPKD.

More Related Videos

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Published on: February 20, 2017

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Related Experiment Videos

Last Updated: May 8, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Published on: February 20, 2017

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Area of Science:

Nephrology
Cardiology
Medical Imaging

Background:

Left ventricular hypertrophy (LVH) is a significant complication in autosomal dominant polycystic kidney disease (ADPKD), linked to arrhythmias, heart failure, and cardiac mortality.
Systemic hypertension, common in ADPKD, drives myocardial remodeling and LVH.
Previous echocardiography studies reported LVH prevalence from 20-40% in ADPKD patients.

Purpose of the Study:

To investigate the evolving prevalence and pathophysiology of LVH in ADPKD patients.
To understand the impact of modern hypertension management and RAAS antagonism on LVH in ADPKD.

Main Methods:

Review of observational studies and the HALT-PKD trial.
Comparison of LVH prevalence using echocardiography versus magnetic resonance imaging (MRI).
Analysis of factors influencing LVH trends, including hypertension control and RAAS inhibitor use.

Main Results:

Recent studies, like HALT-PKD using MRI, show significantly lower LVH prevalence (<4%) compared to older echocardiography data (20-40%).
Improved hypertension detection, control, and increased use of RAAS antagonists are key factors in this trend.
RAAS inhibitors demonstrate potential for LVH regression in ADPKD.

Conclusions:

The pathophysiology and prevalence of LVH in ADPKD appear to be shifting, likely due to advancements in cardiovascular risk management.
Earlier and more effective management of hypertension and the use of RAAS antagonists are crucial for reducing LVH and cardiovascular risk in ADPKD patients.
Ongoing research is vital to further elucidate these evolving relationships and optimize patient care.